Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) always require platelet transfusions, but the increase in platelet count is often less than expected. Since factors responsible for poor response to platelet transfusions in this clinical setting are largely unknown, we performed a prospective study in 87 consecutive children transplanted in a single institution. The mean 16-h corrected count increment (CCI) of 598 platelet transfusions was 5.76 ± 8.32 × 10 9 /l. Both before and after HSCT, 13.8% of patients had antibodies against HLA and/or platelet-specific antigens. Univariate analysis identified 12 factors significantly associated with a lower post-transfusion CCI, but only four reached statistical significance in the multivariate analysis. These four factors were concomitant therapy with vancomycin, alloimmunization, use of an Autopheresis cell separator for preparation of platelet concentrates and cytomegalovirus infection. We, therefore, suggest that a better response to platelet transfusions could be obtained by choosing a suitable cell separator, by avoiding the use of vancomycin and by adopting measures that reduce alloimmunization and CMV infection. Moreover, screening patients for HLA and platelet-specific antibodies before HSCT would identify the majority of subjects who will develop alloimmune refractoriness after transplantation and would allow the search for a compatible donor in advance. Leukemia (2001) 15, 1885-1891.
Introduction
Platelet transfusions for prophylaxis or therapy of hemorrhage are always required by patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) after myeloablative therapy. Unfortunately, the increase in platelet count following an infusion of platelet concentrates (PCs) is often less than expected and sometimes does not significantly alleviate the patient's tendency to bleed, which means frequent platelet support is needed. As a consequence, refractory patients are more often exposed to the risk of transfusion-related adverse events, such as hepatitis, and cost more to treat. 1 Although leukocyte reduction and ultraviolet B irradiation have lowered the frequency of refractoriness to PC transfusion, this problem still occurs in a significant percentage of cases, especially in the clinical setting of HSCT where up to 60% of transfusions are ineffective. [2] [3] [4] Identification of the likely reason for refractoriness in a given individual patient should allow prevention of the problem and development of strategies capable of improving both transfusion practice and patient outcome. A number of clinical trials have evaluated the relative importance of the various causes of poor response to platelet transfusion, and several detrimental factors, both alloimmune and nonalloimmune, have been demonstrated in studies on patients with thrombocytopenia of different origin. 5 Few studies, 4, 6, 7 however, have been performed in the clinical setting of allogeneic HSCT, in which severe immunosuppression is induced by the conditioning regimen and the therapy for prevention of graft-versus-host disease (GVHD). Moreover, no study has specifically addressed this issue in children.
In order to gain further information in this field, we performed a prospective study, evaluating a number of clinical and immune factors which potentially affect or have been previously shown to affect the efficacy of platelet transfusion, 4, 5, [8] [9] [10] [11] [12] [13] in a series of 87 consecutive children who received 598 platelet transfusions after allogeneic HSCT carried out in a single institution.
Materials and methods

Patients
Eighty-seven consecutive children who received an allogeneic HSCT in a single pediatric institution between February 1995 and August 1999 were enrolled in this study. The patients' characteristics at the time of transplantation are reported in Table 1 . All patients but two (one affected by chronic granulomatous disease, and one by mucopolysaccharidosis) had received red blood cells and/or PC transfusions before HSCT. A conditioning regimen consisting of fractionated total body irradiation (TBI) (12 Gy in six divided fractions) and chemotherapy (thiotepa, cyclophosphamide, melphalan, fludarabine) was employed in 49 patients, whereas the remaining 38 were given myeloablative and immunosuppressive drugs (ie busulfan, cyclophosphamide, melphalan, fludarabine) only. In children transplanted from a compatible relative, GVHD prophylaxis consisted of cyclosporin A administered intravenously, starting on day −1, at a dose of 3-5 mg/kg/day for the first 21-28 days, and subsequently at a dose of 6 mg/kg/day orally. Patients transplanted from an HLA-matched unrelated donor were treated, in addition to cyclosporin A, with a short course of methotrexate according to the schedule described by Storb et al, 14 together with either the monoclonal antibody Campath-1 G or anti-lymphocyte globulin, as previously reported. 15 Details of the clinical management after transplantation have been given elsewhere. 16 
Platelet transfusions
Prophylactic platelet transfusions were given to patients with platelet counts lower than 20 × 10 9 /l. Transfusions of PCs were also given to thrombocytopenic patients with a platelet count greater than 20 × 10 9 platelets/l in the presence of active bleeding. PCs obtained by apheresis from single random donors were routinely used, and pooled PCs from single units were used only as emergency transfusions when apheresis PCs were not available. ABO identical units were administered whenever available. When this was not the case, compatible units were given.
The efficacy of each PC transfusion was assessed. A total number of 598 platelet transfusions, given to the 87 patients between the start of the conditioning regimen and day 60 after HSCT, were evaluated.
Preparation of PCs from single units
PCs were prepared by standardized protocols in the blood component laboratory of the Transfusion Center (IRCCS Policlinico San Matteo, Pavia) within 6 h of being collected. The platelet-rich plasma-derived PCs (PRP-PCs) were prepared by the method of Slichter and Harker, 17 while the buffy coatderived PCs (BC-PCs) were prepared using the method of Pietersz et al. 18 The mean platelet content was respectively 70 ± 10.1 × 10 9 /U, and 66 ± 15.1 × 10 9 /U. The white cell contamination was 46 ± 30 × 10 6 /U in the BC-PCs, and about one log higher in the PRP-PCs.
Before being administered, both the PRP-PCs and BC-PCs were treated with ␥-radiation (2500 cGy) by an irradiation device (Gamma Cell Nordion, Kanata, ON, Canada) and filtered through a BIOP 10 PLUS BBS (Biofil-Fresenius, Medolla, Italy).
Preparation of apheresis PCs
All donors complied with Italian recommendations for cytapheresis procedures. All the apheresis PCs were prepared according to the manufacturers' instructions utilizing a closed collection system. The following cell separators were used: (1) Autopheresis-C, PC 5.13 version (Baxter, Deerfield, IL, USA). This is an automated system which collects 600 ml of PRP. A mean of 2.93 × 10 11 platelets/PC was obtained; white blood cell (WBC) content was 330 × 10 9 /PC. All the PCs obtained were filtered through a BIOP 10 PLUS BBS (Biofil-Fresenius, Medolla, Italy); (2) CS-3000 PLUS (Fenwall Division, Deerfield, IL, USA). Platelet collection was obtained by centrifugation with a dual needle procedure (continuous flow) lasting 90 min with a whole blood/ACD ratio of 9-11:1, processing 5000 ml of whole blood. A mean of 4.17 × 10 11 platelets/unit were produced; the average leukocyte count was 171.26 × 10 6 /PC. WBC reduction was obtained by filtration; (3) Amicus (Baxter). This device is based on a centrifugal separation method using plasma recirculation and elutriation. ACD:whole blood ratio was 1:9; the citrate infusion rate was 1.25 mg/kg/min. The harvesting time ranged from 60 to 90 min. A mean of 4.3 × 10 11 platelets/PC was obtained; the residual WBC content was less than 1 × 10 6 /PC. No filtration of these components was performed; (4) COBE Spectra Apheresis System, Version 4.7 and COBE Spectra LRS System, Version 5.1 (COBE BTC, Lakewood, CO, USA). PCs were produced by centrifugation with both the devices with a dual needle procedure lasting 90 min, and an ACD-A/whole blood ratio set at 1:10. A mean of 5.34 × 10 11 platelets/PC was obtained; 80% of the PCs contained less than 1 × 10 6 WBC/PC. Only the PCs with significant leukocyte contamination were filtered. When the COBE LRS System (a biconical flow-chamber mounted in the disposable apheresis set to reduce WBC interference) was employed, WBC contamination of all PCs was less than 1 × 10 6 /PC, so none needed to be filtered; and (5) Apheresis System Technology 204 (Fresenius, Bad Homburg, Germany). All PCs were obtained by centrifugation with a continuous flow procedure. Processing time varied from 80 to 100 min with an ACD/whole blood ratio of 1:10. A mean of 3.43 × 10 11 platelets was obtained, with a WBC content less than 1 × 10 6 /PC. Before administration, all the apheresis PCs were irradiated (2500 cGy).
Pre-transfusion evaluation
The following factors possibly influencing the efficacy of platelet transfusion were considered for evaluation: patient gender, diagnosis, TBI as part of conditioning regimen, type of donor (sibling or unrelated volunteer), human platelet antigen (HPA) typing, serum antibodies against HLA-class I and platelet-specific antigens. Anti-HLA and platelet-specific antibodies were investigated before the conditioning regimen, at recovery from bone marrow aplasia following HSCT (days [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and 40 days after HSCT. At the time of each platelet transfusion we also evaluated: body temperature (dichotomized as р37°C or Ͼ37°C), cytomegalovirus infection (defined as expression of the pp65 viral phosphoprotein on the leukocyte surface), 19 presence and severity of acute GVHD (classified according to Glucksberg et al 20 ) , occurrence of thrombotic thrombocytopenic purpura (defined as microangiopathic hemolytic anemia with fragmentation of more than 5% of erythrocytes and no evidence of disseminated intravascular coagulation), occurrence of active mucosal bleeding (ie hematuria, blood in the stool, gum bleeding or epistaxis), spleen size (less or more than 1 cm below costal margin) or splenectomy before transplantation. Concurrently administered drugs, also recorded, included: i.v. immunoglobulin, corticosteroids, cyclosporin A or tacrolimus, methotrexate, amphotericin B, vancomycin, teicoplanin, ciprofloxacin, amikacin, imipenem-cilastatin, ceftriaxone, ceftazidime, sulfamethoxazole/trimethoprim, hydrocortisone and/or chlorpheniramine just before PC transfusion. Transfusion of erythrocytes or fresh frozen plasma on the some day was also recorded, as were clinically apparent reactions to the PC infusion.
Post-transfusion evaluation
The number of platelets in each PC was recorded and the 16-h post-transfusion corrected count increment (CCI) was calculated according to the formula: CCI (×10 9 /l) = platelet count increment (×10 9 /l) × body surface area (m 2 )/number of platelets transfused ( ×10 11 ). The 16-h post-transfusion platelet count was chosen as the parameter for evaluation because platelet transfusions were usually completed around 5 pm, and platelet counts were routinely performed each morning at approximately 9 am. When additional transfusions of PCs were given on the same day, the 16-h CCI was excluded from the analysis.
Laboratory methods
HPA-1, HPA-2, HPA-3 and HPA-5 genomic typing was accomplished as described previously. 15 Antibodies against HLA-class I antigens, glycoproteins (GP) IIb-IIIa, GPIb-IX and GPIa-IIa were investigated in serum samples by a solid-phase enzyme linked immunoadsorbant assay (PAK 2LE, GTI, Brookfield, WI, USA). To identify specificity of anti-GPIIb-IIIa (HPA-1, HPA-3 and HPA-4) or HLA-class I antibodies, a solid-phase antigen-capture enzyme-linked immunoadsorbant assay (PAK 1 and PRA QIIK-ID; GTI) was used. Analyses and daily quality controls were performed according to the manufacturer's suggestions.
Statistical methods
The actual value of CCI was considered for the analysis; this was preferred to the more traditional dichotomization at 5 in order to maintain all the information available from the data. The association of each of a series of potential risk factors and CCI was assessed by fitting a generalized linear model; HuberWhite robust standard errors were calculated to account for intra-patient correlation of measurements. Post-hoc comparisons were made by the Wald test. Bonferroni correction was further applied to the observed P values to control for multiple test bias. A multivariate model was then fitted that included all variables with a P value Ͻ0.2 at univariate analysis. Predictors' importance was ranked according to their standardized coefficients (not reported). A P value Ͻ0.05 was considered to be statistically significant. Computations were performed using Stata 6.0 for Windows software (StataCorp, College Station, TX, USA).
Results
Overall, 598 platelet transfusions were given to 87 patients. The mean 16-h CCI was 5.76 ± 8.32 × 10 9 /l (with a range comprising between −16 and 75). The percentage of transfusions with a 16-h CCI lower than 5 was 54.4%, which indicated that poor response to platelet transfusion was a common event in this population. Distribution of 16-h CCI is shown in Figure 1 . As reported in Table 2 , the larger part of children were homozygous for HPA polymorphisms, and therefore they were at risk of receiving incompatible PCs. Despite this, evidence of alloimmunization was detected in only 16 patients (Table 3) . Seven children had antibodies against HLA-class I antigens, eight had antibodies against platelet-specific glycoproteins, and one had both types of antibodies. In seven
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Figure 1
Distribution of 16-h CCI after 598 PC transfusions given to 87 patients. Transfusions with a 16-h CCI lower than 5 were 54%. Table 3 Number of patients with serum antibodies against HLAclass I or platelet-specific GPs
Antibody specificity
No. of patients HLA-class I 8
Platelet-specific GP 9
GPIIb-IIIa 5 HPA-3a 1 HPA-4a 4
GPIa-IIa 4
GPIb-IX 1 HPA-specificity of antibodies against GPIIb-IIIa is also reported. Overall, 16 patients were alloimmunized at least at one sampling time, one subject having antibodies against HLA and platelet-specific GPs at the same time. One patient had antibodies against both GPIIb-IIIa and GPIa-IIa.
patients antibodies against HLA-antigens were present before the conditioning regimen and remained detectable throughout the observation period, while in one subject they were absent before transplantation and developed subsequently. In four patients antibodies against platelet-specific antigens were detected before HSCT and subsequently disappeared; in two children they were observed both before and after transplantation, and in three patients they appeared after the allograft. The epitope most frequently recognized by platelet-specific antibodies was within the GPIIb-IIIa complex (HPA-4 in four cases and HPA-3 in one). Univariate analysis evaluating 36 variables was performed in order to identify factors influencing 16-h CCI. Table 4 shows that 12 of them were significantly associated with a poor platelet response. Three variables were patient-related (gender, diagnosis, spleen size or previous splenectomy), two were blood bank-determined (type of PC, type of cell separator), four were therapy-related (treatment with corticosteroid, vancomycin, imipenem-cilastatin and concomitant administration of other blood derivatives) and two derived from alloimmunization (anti-HLA and platelet-specific antibodies). Similar results concerning alloimmunization were obtained including transfusions administered within 7 days of an antibody search (data shown in table) or including all transfusions and considering the results of the nearest test available (data not shown).
Cytomegalovirus infection was associated with a lower CCI, but since all affected patients received either ganciclovir or foscarnet as pre-emptive therapy, it is impossible to attribute the poor platelet response to the infection itself or to its treatment.
In order to assess the relative importance of each factor independently affecting the outcome of platelet transfusions, a multiple linear regression analysis was performed. The 17 variables that at univariate analysis were associated with a lower CCI with a P Ͻ 0.2 were considered eligible for the model, and the presence of collinearity among them was assessed. Patient diagnosis was excluded because alloimmunization was significantly less frequent (P = 0.0004) in subjects with acute leukemia than in those with other disorders. Spleen status, too, was excluded because grade II-IV GVHD affected splenectomized patients (all with a diagnosis of chronic myeloid leukemia or myelodysplastic syndrome) to a lesser extent than subjects with a normal or enlarged spleen (P Ͻ 0.0001). The remaining 15 variables were then subjected to multivariate analysis ( Table 5 ). The factor with the strongest negative impact on CCI was vancomycin therapy. Other strong detrimental factors were alloimmunization to HLAclass I antigens or platelet-specific glycoproteins, as well as the use of PCs obtained from single donors by the Autopheresis cell separator. A borderline P value was obtained for CMV infection. The effect of all other investigated factors was not statistically significant.
Considering platelet transfusions with a 16-h CCI lower than 5, one or more of the five detrimental factors identified by the multivariate analysis were present in 52% of transfusions (data not shown).
Discussion
We studied the efficacy of platelet transfusions given to children during the thrombocytopenic period that follows allogeneic HSCT and showed that poor response was very common, a 16 h-CCI lower than 5 occurring in more than half of transfusions. This result is disappointing but not surprising, since Bishop et al 8 demonstrated that HSCT per se was independently associated with refractoriness to platelet transfusion, and Klumpp et al 6 reported a poor response to platelet transfusion in 64% of transplanted patients. Similar results were recently obtained by Ishida et al, 4 who observed a 16- The multivariate model included all 15 variables with a P value Ͻ0.2 at the univariate analysis. For all separators, the reported P value is for a test of whether each group is different from the Autopheresis-C group. All other comparisons were not significant.
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h CCI lower than 4.5 in 42% of adult patients receiving either an autologous or allogeneic HSCT; moreover, the same authors demonstrated that mean CCI was lower in allogeneic transplants than in autologous ones. Therefore, refractoriness to platelet transfusion remains an outstanding problem in the clinical management of patients receiving allogeneic HSCT. Immune factors including alloantibodies directed towards HLA-antigens and platelet-specific glycoproteins have been considered to be a major cause of refractoriness to platelets in the non-HSCT setting, [21] [22] [23] as roughly 30 to 70% of multiply transfused patients developed alloimmunization. However, the routine use of leukocyte-depleted blood products has lowered the incidence of alloimmunization to nearly 25% in the overall population and to nearly 15% both in women who have never been pregnant and in men. 3 Our study enrolling children exclusively confirms the low rate of alloimmunization in subjects who have never been pregnant. In fact, before HSCT 13.8% of patients were alloimmunized as a consequence of previous transfusions, antibodies against HLA molecules being slightly more common than those towards platelet-specific antigens. Moreover, probably due to severe immunosuppression produced by conditioning regimens and therapy for prevention of GVHD, the percentage of alloimmunization did not increase after HSCT, in that 4.6% of children developed de novo alloimmunization and 4.6% became negative.
The overall rate of alloimmunization in our patients was lower than that previously reported by Ishida et al 4 in adult subjects undergoing allogeneic or autologous HSCT (26.2%). This difference is even more evident considering de novo alloimmunization after HSCT (19.0% in the case series of Ishida). Several explanations are possible for this discrepancy, and we cannot resolve whether it derived from different sensitivityspecificities of the laboratory tests for antibody detection or from differences in the patient populations (for example, adults patients investigated by Ishida, children by us), or from differences in the conditioning treatments or immunosuppressive regimens used for GVHD prophylaxis.
Although alloimmunization was rare in our children, when it occurred it became a major factor associated with ineffective platelet transfusion, as documented by both univariate and multivariate analysis (Tables 4 and 5 ). This conclusion confirms previous data obtained in patient populations comprising transplanted and not-transplanted subjects. 9, 24 However, different results were observed in the HSCT setting by Ishida et al, 4 who reported that antibodies to HLA-antigens had a relatively insignificant impact on 16-h CCI, while platelet-specific antibodies enhanced post-transfusion platelet efficacy. Since it is not possible to conciliate such opposite results, we are compelled to conclude that some confounding factor was unrecognized in one or other of the case series.
Besides alloimmunization, univariate analysis identified 12 additional factors predicting a poor response to platelet transfusions (Table 4) , most of them previously identified outside the HSCT setting. However, only three survived multivariate analysis: use of the Autopheresis-C cell separator to prepare the apheresis PCs, CMV infection, and therapy with vancomycin. Vancomycin administration was the factor with the strongest statistical association with a poor response to PC transfusions. This association had been previously identified in a series of platelet transfusions given to patients with thrombocytopenia of different origin. 10 Moreover, several cases of vancomycin-induced thrombocytopenia have been reported and it has been suggested that this adverse effect derives from an immune mechanism or from a direct toxic effect. [25] [26] [27] Thus, vancomycin has been suspected for some time now to interfere with platelet count, and our observation further supports this hypothesis. However, vancomycin was administered on the basis of results of in vitro tests of antimicrobial activity, and we cannot exclude for certain that children given this drug were a selected population, with peculiar infections favoring a poor response to platelet transfusions.
The use of PCs obtained by the Autopheresis cell separator was another strong and independent factor detrimental to successful platelet transfusion. This instrument differs from the others we used in that it utilizes membrane filtration in addition to centrifugation to collect platelets. Moreover, WBC contamination during PC collection was higher than that with the other instruments. Both artificial membranes 28 and WBC 29 are known to activate platelets and to induce a storage lesion in PCs that could justify their lower in vivo efficacy. The negative effect of CMV infection on the outcome of platelet transfusions is reported here for the first time. The detrimental effect of CMV was weaker than that of vancomycin, alloimmunization or cell separator type, and its statistical significance was borderline. While it is well known that CMV can be cytotoxic for megakaryocytes and marrow stromal cells, 30 a direct effect on platelets has never been described. Since our data do not exclude that conditions associated with CMV infection (such as anti-CMV therapy, the longer delay in platelet recovery after transplantation of patients who experienced reactivation of infection, etc) were responsible for the lower CCI, specific studies to address this issue are warranted.
One or more of the five factors identified as independent detrimental factors were present in 52% of the platelet transfusions which produced a 16-h CCI lower than 5. Therefore, unidentified factors were responsible for the unsatisfactory outcome of platelet transfusions in at least 48% of cases, and further investigation is needed to identify these factors. However, our study indicates that the outcome of PC transfusion in children after allogeneic HSCT could be improved by simple measures, such as avoiding the use of vancomycin and utilizing a suitable cell separator for PC preparation. Vancomycin can be efficiently replaced by teicoplanin, which has a similar antibacterial spectrum and did not affect platelet transfusion outcome, and the Autopheresis cell separator can be replaced by one of the other instruments that resulted in better clinical results. Since CMV infection was significantly associated with poor response to platelet transfusion, the use of PCs from seronegative donors and/or leukocyte depletion of PCs are strongly recommended in seronegative HSCT donor/recipient pairs. 31 Our study clearly shows that alloimmunization greatly reduced the efficacy of platelet transfusions. On this basis, measures effective in preventing alloimmunization, such as the reduction of leukocytes by filtration and ultraviolet irradiation of PCs, 3 are mandatory in this clinical setting. When alloimmunization and refractoriness develop despite these measures, matched platelet transfusions are required. 32 The search for a compatible donor can be time-consuming, and a delay in PC infusion may be dangerous in patients with active bleeding or severe thrombocytopenia. However, in the clinical setting of HSCT we can gain advantage from the fact that de novo alloimmunization is rare after transplantation and the majority of subjects who will develop alloimmune refractoriness can be identified before their allograft by a search for antibodies directed towards HLA or platelet-specific antigens. Early recognition of patients at risk of alloimmune refractoriness could allow identification of a compatible donor in advance and could shorten the time required to give efficient platelet support if refractoriness occurs.
In conclusion, poor response to platelet transfusions is observed frequently after HSCT, but simple measures could significantly reduce both the frequency and the clinical severity of this complication.
